Doric Nimrod Air One Share Discussion Threads

[waldron] 26/5/2006 08:36

ZURICH (AFX) - Share prices are expected to open markedly higher tracking overnight US and Tokyo gains, and rebounding from sharp losses last week, traders said.

In pre-bourse trading, the Swiss Market Index was 92.40 points higher at 7,573.80.

On Wednesday, the last trading day ahead of the Ascension day holiday, the SMI closed down 91.14 points or 1.20 pct at 7,481.33, and the SPI was down 65.10 points or 1.10 pct at 5,824.15.



COMPANY NEWS

-UBS to buy ABN Amro's futures and options business for 386 mln usd

-SWX probes ADB for possible breach of disclosure rules

-Swisslog says nearly all rights exercised in 73.2 mln sfr capital hike

-Roche affiliate Genentech climbs on FDA filing for Avastin

-Swiss companies legally obliged to reveal pay of CEOs, directors



MARKET NEWS/SENTIMENT

-Given a dearth of market-moving corporate news here, trading volumes will likely be thin today ahead of the weekend and the US and UK holidays Monday. Still, the Swiss Market looks set to recoup some of its severe recent losses.

[e-mail]

at/cw/ckj/jfr

[waldron] 02/3/2006 07:28

Novartis files Lucentis for EU approval for wet AMD

ZURICH (AFX) - Novartis AG said that its has filed Lucentis for European
Union approval for the treatment of neovascular age-related macular degeneration
("wet AMD"), the leading cause of blindness in people over age 60 in the West.
Novartis also submitted Lucentis for approval in Switzerland in February.
Genentech Inc, which holds marketing rights for the drug in the US and
Canada, said earlier this week that the FDA has given the green light for a
6-month priority review.
Genentech is majority owned by Roche Holding AG.

[e-mail]
scs/lam

[grupo] 13/2/2006 10:35

Roche Seen Down On Genentech Drug News

Monday, February 13, 2006 3:59:05 AM ET
Dow Jones Newswires



0744 GMT [Dow Jones] Roche (RHHBY) stock is likely to open lower on news Genentech (DNA), majority-owned by Roche, is temporarily suspending recruitment of patients for Avastin drug trial. "We see a downside potential of 3%-4% short-term, although this is just one of many studies involving Avastin," strategist says. Shares closed at CHF191.90. (MGE)

[ariane] 05/2/2006 08:45

Toshiba Corp Toshiba to enter DNA chip business next year - report
TOKYO (AFX) - Toshiba Corp will enter the DNA chip market by releasing
advanced chips and a chip analyzer as early as next year, the Nihon Keizai
Shimbun reported at the weekend, citing sources in the company.
The newspaper, in its on-line edition, said Toshiba has already developed
prototypes of DNA chips designed to assess, through gene analysis, the optimum
dose of rheumatism medicine for individual patients and their vulnerability to
side effects, in partnership with Tokyo Women's Medical University.
It has started clinical research on the chips.
The company is also pushing forward, in partnership with Osaka University,
with similar research on chips intended to assess tuberculosis and cancer drugs.
It plans to develop a prototype of an automatic DNA chip analyzer by the end
of this year.
Unlike most of the DNA chips now in research use, which employ a fluorescent
material to illuminate the target genes, Toshiba's prototype is designed to
detect the number of genes electrically.
The firm's proprietary DNA chips are more sensitive than conventional ones
and offer almost 100 pct accuracy, compared to rates of 80-90 pct for regular
chips, the Nikkei reported.
jm

[grupo guitarlumber] 30/12/2005 15:34

Genentech submits Biologics Licence Application for Lucentis eye drug

ZURICH (AFX) - Genentech Inc., the US biotech group in which Switzerland's
Roche Holding AG holds a majority stake, said it has submitted a Biologics
License Application (BLA) to the US Food and Drug Administration for the use of
eye drug Lucentis in the treatment of neovascular wet age-related macular
degeneration.
As part of the submission, the group has requested a Priority Review from
the FDA, which, if okayed, would give the latter six months from the receipt of
the submission to take action on the application, it said.
Age-related macular degeneration (AMD) occurs in both dry and wet form. It
is the number one cause of blindness for people over the age of 60.
The wet form is caused by growth of abnormal blood vessels which leak fluid
and blood thereby causing scar tissue that destroys the retina which results in
a deterioration of sight.
Lucentis, which is developed jointly by Genentech and the Novartis
Ophthalmics unit, is designed to block new blood vessel growth and leaks.
[e-mail]
ckj/jsa

[waldron] 08/11/2005 11:30

Novartis, Roche Pfts Seen Aided By Lucentis

Tuesday, November 08, 2005 5:38:23 AM ET
Dow Jones Newswires



1016 GMT [Dow Jones] Genentech (DNA) and Novartis (NVS) release phase-III data for Lucentis in age-related macular degeneration. Study data showing strong efficacy should mean Lucentis can start replacing Visudyne, says Lombard Odier Darier Hentsch. Estimates worldwide sales up to $2B, around half of which would be booked by Novartis. That means Lucentis would add low single-digit net profit increase for both Novartis and - via Genentech - for Roche (RHHBY) by '10, says LODH. LODH Plans to revise estimates. Reiterates Novartis and Roche at buy, targets are CHF83 and CHF225. Novartis +0.4% at CHF71.35, Roche +1.2% at CHF197.20.

[waldron] 08/11/2005 09:31

Burglar kidnaps parrot

A burglar abducted a parrot - fearing it would reveal his identity to police.

Monty, an African Grey parrot, was the only witness as David Carlile, 32, stole antiques, jewellery and cash from an isolated country house.

When he was arrested and asked why he took the bird Carlile said: "Parrots can talk and I didn't want it grassing me up."

According to The Sun a police spokesman said: "We were in stitches. This guy really thought we could interview the parrot.

"It's just as well we nicked him through fingerprints and DNA - I wouldn't have liked to have introduced the parrot to a judge as our chief prosecution witness. Monty remains at large after being sold. But at least Carlile is doing some bird."

Carlile, of Bristol, admitted more than 100 burglaries throughout Berkshire and was jailed for seven years at Swindon Crown Court.

Monty's owner Diana Winter appealed for his safe return.

The seven-year-old has red feathers in his tail and a blue plastic ring on his foot. He eats only white grapes.

[ariane] 27/10/2005 08:24

Medical marketing gets 4th DNA vaccine patent; sees flu potential

LONDON (AFX) - Medical Marketing International Group PLC said its Genvax
unit has been granted a fourth patent for its DNA vaccines for cancer and
infectious diseases, including possibly flu.
Chairman David Best said the new European patent provides additional
protection for technology which has "great potential in infectious diseases such
as pandemic influenza as they can be rapidly developed and manufactured in
response to such threats."
He added that the strengthening patent portfolio "enhances our vaccine
pipeline and similarly provides greater leverage to the current negotiations we
are having with major pharmaceutical companies."
[e-mail]
jm/

[ariane] 20/10/2005 06:50

Genentech in collaboration to explore Avastin for brain cancer treatment

BURLINGAME, Calif (AFX) - Genentech Inc said it has entered into a
collaboration with Accelerate Brain Cancer Cure (ABC 2), a non-profit
foundation, to explore the potential of Avastin for treating patients with
glioblastoma multiforme (GBM), an especially deadly form of brain cancer.
The collaboration is focused on a novel imaging study of patients with
recurrent GBM who are enrolled in a Phase II clinical trial at Duke University.
The two parties will initially share development expenses and if the results are
successful, ABC (2) will provide access to its resources for a
Genentech-sponsored randomized clinical trial in relapsed GBM.
"Encouraging preliminary data from early-stage research of Avastin in
glioblastoma multiforme led us to initiate a Phase II study to gain further
insight into Avastin's potential role in this setting," said Gwen Fyfe,
Genentech's vice president of Clinical Hematology/Oncology.
[e-mail]
ak/

[ariane] 19/10/2005 07:09

Roche 9-mths sales up 17 pct, narrowly beats consensus UPDATE

(updates with more details on nine months sales)
ZURICH (AFX) - Roche Holding AG said that nine months sales were 25.442 bln
sfr, up 17 pct in local currencies, narrowly beating marketing consensus of
25.145 bln.
Pharma division sales rose 20 pct, or 22 pct in local currencies, to 19.434
bln sfr, beating consensus of 19.142 bln, while sales in the Diagnostics
division were up 4 pct in local currencies to 6.008 bln, in line with forecasts.
The Swiss group said that sales growth in the pharma division was more than
three times as fast as the global market, thanks to continued strong sales of
oncology drugs -- fruits of its tie-up with Genentech Inc -- and of Tamiflu as
governments stockpile for a possible flu pandemic.
Oncology sales alone rose 37 pct, with sales of colorectal cancer drug
Avastin up 148 pct to 1.1 bln sfr, NHL drug MabThera/Rituxan -- its top selling
drug -- up 22 pct to 3.0 bln and breast cancer drug Herceptin up 38 pct to 1.4
bln.
Xeloda sales were up 47 pct at 568 mln sfr, and sales of non-small cell lung
cancer drug Tarceva totaled 234 mln after 11 months on the US market.
In virology, Tamiflu sales rose 263 pct to 859 mln, hepatitis C and B drug
Pegasys sales rose 17 pct to 1.0 bln, and anti-HIV treatment Fuzeon sales rose
49 pct to 178 mln.
In anemia, the group's second biggest product NeoRecormon/Epogin saw sales
rise 7 pct to 1.7 bln, and in transplantation CellCept sales rose 18 pct to 1.2
bln.
[e-mail]
scs/hjp/jfr

[ariane] 14/10/2005 09:27

Leu Ups Roche To Buy, Lifts Target To CHF210

Friday, October 14, 2005 3:37:25 AM ET
Dow Jones Newswires



0718 GMT [Dow Jones] Bank Leu raises Roche (RHHBY) to buy from hold, target to CHF210 from CHF186 following strong 3Q from Genentech (DNA) and ahead of Roche's own 9 months results. "Looking into 2006 we see ample clinical and regulatory newsflow that is expected to drive the share price." Roche +0.1% at CHF184.80. (HJS)

[grupo] 07/10/2005 07:46

Roche to launch system for high-throughput DNA sequencing

ZURICH (AFX) - Roche Holding AG said it is launching the Genome Sequencer 20
System and reagents, a technology enabling researchers to sequence genomes and
long DNA sequences up to 100 times faster than current commercial platforms.
The product, it said, features a nanotechnology-based approach to sequencing
invented by the US-based 454 Life Sciences.
Roche said its Diagnostics division will offer the Genome Sequencer 20
System and reagents and that 454 Life Sciences will continue to manufacture
instrument systems and reagent kits for its Diagnostics unit.
454 Life Sciences also has the option to transfer the responsibility for
reagent manufacturing to Roche Diagnostics if sales volume are sufficient.
[e-mail]
ckj/jsa